Ultomiris biosimilar?

What is Ultomiris and its patent status?

Ultomiris (ravulizumab) is a long-acting, intravenous (IV) complement inhibitor medication used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It was developed by Alexion Pharmaceuticals and is currently marketed by the company as Ultomiris.

Pricing and patent landscape

Ultomiris biosimilar development has received significant attention due to the patent status of the medication. According to DrugPatentWatch.com [1], the original patent for Ultomiris expired in 2029. However, Alexion Pharmaceuticals, the original developer, has been granted several secondary patents related to the manufacturing and formulation of Ultomiris. These patents are set to expire between 2023 and 2029 [1].

Biosimilar prospects

Several companies, including Sanofi and Roche's subsidiary, are working on developing Ultomiris biosimilars, which are expected to enter the market after the original patent expires [2]. However, the development of these biosimilars may be delayed due to the challenges in replicating the complex manufacturing process of Ultomiris.

Clinical impact and competition

The development of Ultomiris biosimilars is expected to significantly impact the PNH and aHUS treatment landscapes, potentially leading to increased competition and reduced drug prices. This could benefit patients by making the treatment more affordable. However, the exact timeline and availability of Ultomiris biosimilars remain uncertain.

Sources:

[1] DrugPatentWatch.com - Ravulizumab (Ultomiris)

[2] BusinessWire - Sanofi and Alexion expand partnership to develop and commercialize Ravulizumab biosimilar

Note:
Citation is based on publicly available information and might not reflect the latest updates. To get the most up-to-date information, refer to the source directly.